HC Wainwright Has Bearish Estimate for OVID FY2025 Earnings

Ovid Therapeutics (NASDAQ:OVID) – Stock analysts at HC Wainwright cut their FY2025 earnings estimates for shares of Ovid Therapeutics in a research note issued to investors on Monday, November 24th. HC Wainwright analyst R. Selvaraju now anticipates that the company will post earnings of ($0.49) per share for the year, down from their previous estimate of ($0.46). HC Wainwright has a “Buy” rating and a $2.00 price objective on the stock. The consensus estimate for Ovid Therapeutics’ current full-year earnings is ($0.40) per share. HC Wainwright also issued estimates for Ovid Therapeutics’ Q4 2025 earnings at ($0.11) EPS, Q1 2026 earnings at ($0.09) EPS, Q3 2026 earnings at ($0.08) EPS, Q4 2026 earnings at ($0.09) EPS and FY2026 earnings at ($0.35) EPS.

Ovid Therapeutics (NASDAQ:OVID) last issued its earnings results on Wednesday, November 12th. The company reported ($0.17) earnings per share for the quarter, missing the consensus estimate of ($0.15) by ($0.02). The firm had revenue of $0.13 million during the quarter, compared to analysts’ expectations of $0.17 million. Ovid Therapeutics had a negative net margin of 550.04% and a negative return on equity of 63.79%.

Other equities analysts also recently issued reports about the company. Leerink Partners started coverage on Ovid Therapeutics in a research note on Monday, November 17th. They set an “outperform” rating and a $5.00 target price for the company. Wall Street Zen cut Ovid Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, November 15th. Leerink Partnrs upgraded shares of Ovid Therapeutics to a “strong-buy” rating in a research report on Monday, November 17th. B. Riley reaffirmed a “buy” rating on shares of Ovid Therapeutics in a research note on Friday, October 10th. Finally, Oppenheimer started coverage on shares of Ovid Therapeutics in a report on Thursday, October 9th. They issued an “outperform” rating and a $7.00 price target for the company. Two analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus price target of $4.00.

Ovid Therapeutics Price Performance

Shares of OVID opened at $1.63 on Wednesday. Ovid Therapeutics has a twelve month low of $0.24 and a twelve month high of $2.01. The stock’s 50 day moving average is $1.47 and its two-hundred day moving average is $0.91. The firm has a market capitalization of $116.07 million, a PE ratio of -3.26 and a beta of 0.32. The company has a current ratio of 4.24, a quick ratio of 4.24 and a debt-to-equity ratio of 0.28.

Institutional Investors Weigh In On Ovid Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the business. XTX Topco Ltd acquired a new stake in Ovid Therapeutics in the 1st quarter valued at about $29,000. Private Advisor Group LLC purchased a new stake in shares of Ovid Therapeutics in the third quarter valued at about $33,000. Apollon Wealth Management LLC acquired a new stake in shares of Ovid Therapeutics in the third quarter valued at approximately $36,000. Nuveen LLC acquired a new position in shares of Ovid Therapeutics during the 1st quarter worth approximately $37,000. Finally, Jane Street Group LLC purchased a new stake in Ovid Therapeutics in the 2nd quarter valued at approximately $47,000. 72.24% of the stock is currently owned by hedge funds and other institutional investors.

About Ovid Therapeutics

Ovid Therapeutics Inc, a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies.